{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:47:00Z","timestamp":1769600820320,"version":"3.49.0"},"reference-count":61,"publisher":"Portland Press Ltd.","issue":"1","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7,1]]},"abstract":"<jats:p>In the present paper we demonstrate that the cytostatic and antiviral activity of pyrimidine nucleoside analogues is markedly decreased by a Mycoplasma hyorhinis infection and show that the phosphorolytic activity of the mycoplasmas is responsible for this. Since mycoplasmas are (i) an important cause of secondary infections in immunocompromised\u00a0(e.g. HIV infected) patients and (ii) known to preferentially colonize tumour tissue in cancer patients, catabolic mycoplasma enzymes may compromise efficient chemotherapy of virus infections and cancer. In the genome of M. hyorhinis, a TP (thymidine phosphorylase) gene has been annotated. This gene was cloned, expressed in Escherichia coli and kinetically characterized. Whereas the mycoplasma TP efficiently catalyses the phosphorolysis of thymidine (Km=473\u00a0\u03bcM) and deoxyuridine (Km=578\u00a0\u03bcM), it prefers uridine (Km=92\u00a0\u03bcM) as a substrate. Our kinetic data and sequence analysis revealed that the annotated M. hyorhinis TP belongs to the NP (nucleoside phosphorylase)-II class PyNPs (pyrimidine NPs), and is distinct from the NP-II class TP and NP-I class UPs (uridine phosphorylases). M. hyorhinis PyNP also markedly differs from TP and UP in its substrate specificity towards therapeutic nucleoside analogues and susceptibility to clinically relevant drugs. Several kinetic properties of mycoplasma PyNP were explained by in silico analyses.<\/jats:p>","DOI":"10.1042\/bj20112225","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T11:13:42Z","timestamp":1333624422000},"page":"113-123","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Characterization of pyrimidine nucleoside phosphorylase of<i>Mycoplasma hyorhinis<\/i>: implications for the clinical efficacy of nucleoside analogues"],"prefix":"10.1042","volume":"445","author":[{"given":"Johan","family":"Vande Voorde","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, blok x \u2013 bus 1030, B-3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Gago","sequence":"additional","affiliation":[{"name":"Departamento de Farmacolog\u00eda, Universidad de Alcal\u00e1, E-28871 Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristof","family":"Vrancken","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, blok x \u2013 bus 1030, B-3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Liekens","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, blok x \u2013 bus 1030, B-3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Balzarini","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, blok x \u2013 bus 1030, B-3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2012,6,15]]},"reference":[{"key":"2021112215243827100_B1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(02)00788-X","article-title":"Nucleoside analogues and nucleobases in cancer treatment","volume":"3","author":"Galmarini","year":"2002","journal-title":"Lancet Oncol."},{"key":"2021112215243827100_B2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","author":"De Clercq","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"2021112215243827100_B3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bcp.2008.04.019","article-title":"The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: implications for cancer therapy","volume":"76","author":"Bronckaers","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"2021112215243827100_B4","first-page":"2175","article-title":"Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection","volume":"28","author":"Jett\u00e9","year":"2008","journal-title":"Anticancer Res."},{"key":"2021112215243827100_B5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S1470-2045(09)70037-3","article-title":"Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes","volume":"10","author":"Liekens","year":"2009","journal-title":"Lancet Oncol."},{"key":"2021112215243827100_B6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bcp.2011.05.024","article-title":"The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2\u2032-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes","volume":"82","author":"Vande Voorde","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"2021112215243827100_B7","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1128\/MMBR.62.4.1094-1156.1998","article-title":"Molecular biology and pathogenicity of mycoplasmas","volume":"62","author":"Razin","year":"1998","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"2021112215243827100_B8","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1093\/clinids\/17.Supplement_1.S243","article-title":"Extragenital Mycoplasma hominis infections in adults: emphasis on immunosuppression","volume":"17","author":"Meyer","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"2021112215243827100_B9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/00063198-200305000-00009","article-title":"HIV-related pulmonary infections: a review of the recent literature","volume":"9","author":"Wolff","year":"2003","journal-title":"Curr. Opin. Pulm. Med."},{"key":"2021112215243827100_B10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1006\/gyno.1996.0316","article-title":"Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR-ELISA","volume":"63","author":"Chan","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"2021112215243827100_B11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/gyno.1998.5177","article-title":"Assessment of archived paraffin-embedded cervical condyloma tissues for mycoplasma-conserved DNA using sensitive PCR-ELISA","volume":"71","author":"Kidder","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"2021112215243827100_B12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3748\/wjg.v7.i2.266","article-title":"Mycoplasma infections and different human carcinomas","volume":"7","author":"Huang","year":"2001","journal-title":"World J. Gastroenterol."},{"key":"2021112215243827100_B13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.lungcan.2004.01.007","article-title":"Does Mycoplasma sp. play role in small cell lung cancer?","volume":"45","author":"Pehlivan","year":"2004","journal-title":"Lung Cancer"},{"key":"2021112215243827100_B14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.urology.2004.10.015","article-title":"Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma?","volume":"65","author":"Pehlivan","year":"2005","journal-title":"Urology"},{"key":"2021112215243827100_B15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-230X-10-132","article-title":"Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells","volume":"10","author":"Yang","year":"2010","journal-title":"BMC Gastroenterol."},{"key":"2021112215243827100_B16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1749-8090-6-137","article-title":"Bacterial and fungal microflora in surgically removed lung cancer samples","volume":"6","author":"Apostolou","year":"2011","journal-title":"J. Cardiothorac. Surg."},{"key":"2021112215243827100_B17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/1471-2407-11-233","article-title":"Detection of antibodies directed at M. hyorhinis p37\u00a0in the serum of men with newly diagnosed prostate cancer","volume":"11","author":"Urbanek","year":"2011","journal-title":"BMC Cancer"},{"key":"2021112215243827100_B18","doi-asserted-by":"crossref","first-page":"7247","DOI":"10.1021\/jm200815w","article-title":"Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside","volume":"54","author":"McGuigan","year":"2011","journal-title":"J. Med. Chem."},{"key":"2021112215243827100_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3610001","article-title":"Structural analyses reveal two distinct families of nucleoside phosphorylases","volume":"361","author":"Pugmire","year":"2002","journal-title":"Biochem. J."},{"key":"2021112215243827100_B20","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2032-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"2021112215243827100_B21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0014-5793(98)01271-X","article-title":"7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase","volume":"438","author":"Balzarini","year":"1998","journal-title":"FEBS Lett."},{"key":"2021112215243827100_B22","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1128\/JB.00946-10","article-title":"Complete genome sequence of Mycoplasma hyorhinis strain HUB-1","volume":"192","author":"Liu","year":"2010","journal-title":"J Bacteriol."},{"key":"2021112215243827100_B23","doi-asserted-by":"crossref","first-page":"29598","DOI":"10.1074\/jbc.M402602200","article-title":"The nucleoside derivative 5\u2032-O-trityl-inosine (KIN59) suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action","volume":"279","author":"Liekens","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021112215243827100_B24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nprot.2009.2","article-title":"Protein structure prediction on the web: a case study using the Phyre server","volume":"4","author":"Kelley","year":"2009","journal-title":"Nat. Protoc."},{"key":"2021112215243827100_B25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/bjc.1995.392","article-title":"Increased sensitivity to the prodrug 5\u2032-deoxy-5-fluorouridine and modulation of 5-fluoro-2\u2032-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase","volume":"72","author":"Patterson","year":"1995","journal-title":"Br. J. Cancer"},{"key":"2021112215243827100_B26","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/0006-2952(83)90307-6","article-title":"Phosphorolysis of (E)-5-(2-bromovinyl)-2\u2032-deoxyuridine (BVDU) and other 5-substituted-2\u2032-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets","volume":"32","author":"Desgranges","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"2021112215243827100_B27","first-page":"K35","article-title":"(E)-5-(2-Bromovinyl)-2\u2032-deoxyuridine: a good substrate for mammalian pyrimidine nucleoside phosphorylases","volume":"42","author":"Liermann","year":"1983","journal-title":"Biomed. Biochim. Acta"},{"key":"2021112215243827100_B28","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1124\/mol.61.5.1140","article-title":"Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase","volume":"61","author":"Balzarini","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"2021112215243827100_B29","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/JB.05505-11","article-title":"Genome analysis of a Mycoplasma hyorhinis strain derived from a primary human melanoma cell line","volume":"193","author":"Kornspan","year":"2011","journal-title":"J. Bacteriol."},{"key":"2021112215243827100_B30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/14.6.523","article-title":"Homology modeling, model and software evaluation: three related resources","volume":"14","author":"Rodriguez","year":"1998","journal-title":"Bioinformatics"},{"key":"2021112215243827100_B31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.str.2003.11.018","article-title":"Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor","volume":"12","author":"Norman","year":"2004","journal-title":"Structure"},{"key":"2021112215243827100_B32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/bi034793o","article-title":"Role of histidine85 in the catalytic mechanism of thymidine phosphorylase as assessed by targeted molecular dynamics simulations and quantum mechanical calculations","volume":"43","author":"Mendieta","year":"2004","journal-title":"Biochemistry"},{"key":"2021112215243827100_B33","first-page":"3687","article-title":"Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines","volume":"53","author":"el Kouni","year":"1993","journal-title":"Cancer Res."},{"key":"2021112215243827100_B34","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1016\/S0021-9258(18)83424-X","article-title":"Purification and comparative properties of a pyrimidine nucleoside phosphorylase from Bacillus stearothermophilus","volume":"244","author":"Saunders","year":"1969","journal-title":"J. Biol. Chem."},{"key":"2021112215243827100_B35","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/S0021-9258(19)34157-2","article-title":"Purification and substrate specificity of pyrimidine nucleoside phosphorylase from Haemophilus influenzae","volume":"246","author":"Scocca","year":"1971","journal-title":"J. Biol. Chem."},{"key":"2021112215243827100_B36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0166-6851(88)90096-5","article-title":"Purification and characterization of uridine (thymidine) phosphorylase from Giardia lamblia","volume":"30","author":"Lee","year":"1988","journal-title":"Mol. Biochem. Parasitol."},{"key":"2021112215243827100_B37","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1016\/S0021-9258(18)77450-4","article-title":"Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 \u00c5 resolution","volume":"265","author":"Walter","year":"1990","journal-title":"J. Biol. Chem."},{"key":"2021112215243827100_B38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/jmbi.1998.1941","article-title":"Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase","volume":"81","author":"Pugmire","year":"1998","journal-title":"J. Mol. Biol."},{"key":"2021112215243827100_B39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1349-7006.2007.00477.x","article-title":"Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies","volume":"98","author":"Temmink","year":"2007","journal-title":"Cancer Sci."},{"key":"2021112215243827100_B40","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/07357900802087242","article-title":"Phase I clinical study of three times a day oral administration of TAS-102\u00a0in patients with solid tumors","volume":"26","author":"Overman","year":"2008","journal-title":"Cancer Invest."},{"key":"2021112215243827100_B41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10637-008-9142-3","article-title":"Phase 1 study of TAS-102 administered once daily on a 5-day-per\u2013week schedule in patients with solid tumors","volume":"26","author":"Overman","year":"2008","journal-title":"Invest. New Drugs"},{"key":"2021112215243827100_B42","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/0006-2952(82)90488-9","article-title":"5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase","volume":"31","author":"Niedzwicki","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"2021112215243827100_B43","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1016\/0006-2952(86)90675-1","article-title":"Inhibition of uridine phosphorylase from Escherichia coli by benzylacyclouridines","volume":"35","author":"Park","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"2021112215243827100_B44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1432-1033.1993.tb17651.x","article-title":"Thymidine phosphorylase activity of platelet-derived endothelial growth factor is responsible for endothelial cell mitogenicity","volume":"212","author":"Finnis","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"2021112215243827100_B45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF01567401","article-title":"Uridine phosphorylase activity among the class Mollicutes","volume":"12","author":"McGarrity","year":"1985","journal-title":"Curr. Microbiol."},{"key":"2021112215243827100_B46","first-page":"211","article-title":"Sources of nucleotides","volume-title":"Mycoplasmas, Molecular Biology and Pathogenesis","author":"Finch","year":"1992"},{"key":"2021112215243827100_B47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-4827(72)90484-3","article-title":"Mycoplasma contamination of animal cell cultures: a simple, rapid detection method","volume":"74","author":"Levine","year":"1972","journal-title":"Exp. Cell Res."},{"key":"2021112215243827100_B48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0014-4827(74)90411-X","article-title":"Incorporation of 3H-uridine and 3H-uracil into RNA: a simple technique for the detection of mycoplasma contamination of cultured cells","volume":"84","author":"Schneider","year":"1974","journal-title":"Exp. Cell Res."},{"key":"2021112215243827100_B49","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1128\/jb.175.16.5281-5285.1993","article-title":"Identification of Mycoplasma pirum genes involved in the salvage pathways for nucleosides","volume":"175","author":"Tham","year":"1993","journal-title":"J. Bacteriol."},{"key":"2021112215243827100_B50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1590\/S1415-47572007000200005","article-title":"Purine and pyrimidine nucleotide metabolism in Mollicutes","volume":"30","author":"Bizarro","year":"2007","journal-title":"Genet. Mol. Biol."},{"key":"2021112215243827100_B51","doi-asserted-by":"crossref","first-page":"10268","DOI":"10.1073\/pnas.93.19.10268","article-title":"A minimal gene set for cellular life derived by comparison of complete bacterial genomes","volume":"93","author":"Mushegian","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021112215243827100_B52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1073\/pnas.0510013103","article-title":"Essential genes of a minimal bacterium","volume":"103","author":"Glass","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021112215243827100_B53","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1126\/science.1176343","article-title":"Proteome organization in a genome-reduced bacterium","volume":"326","author":"Kuhner","year":"2009","journal-title":"Science"},{"key":"2021112215243827100_B54","first-page":"1094","article-title":"Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice","volume":"46","author":"Desgranges","year":"1986","journal-title":"Cancer Res."},{"key":"2021112215243827100_B55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(97)00377-7","article-title":"Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine","volume":"122","author":"Ogura","year":"1998","journal-title":"Cancer Lett."},{"key":"2021112215243827100_B56","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0026-895X(24)26498-1","article-title":"Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH","volume":"57","author":"Nishiyama","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"2021112215243827100_B57","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF01221032","article-title":"Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2\u2032-deoxyuridine","volume":"120","author":"Keizer","year":"1994","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2021112215243827100_B58","first-page":"270","article-title":"Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs","volume":"25","author":"Okuda","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"2021112215243827100_B59","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3565(24)37858-9","article-title":"A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs","volume":"287","author":"Okuda","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021112215243827100_B60","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01314875","article-title":"Analysis of the TK enzyme complex induced by HSV types\u00a01 and 2 by means of isoelectric focusing and polyacrylamide gel electrophoresis","volume":"71","author":"Labenz","year":"1982","journal-title":"Arch. Virol."},{"key":"2021112215243827100_B61","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1016\/0006-2952(82)90594-9","article-title":"5-Substituted 2\u2032-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase","volume":"31","author":"Balzarini","year":"1982","journal-title":"Biochem. Pharmacol."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/445\/1\/113\/669932\/bj4450113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/445\/1\/113\/669932\/bj4450113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T14:32:37Z","timestamp":1742913157000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/445\/1\/113\/45863\/Characterization-of-pyrimidine-nucleoside"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bj20112225","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,15]]}}}